Expected pCR with NAC is approximately 30% in HER2-positive and 30 to 50% in triple-negative histology, whilst it is less than 10% in hormone-positive and HER2-negative breast cancer patients [6–8]. The gene discussed is ERBB2; the disease is breast carcinoma.